Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tilman Speicher

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Diagnostics (Basel, Switzerland)|October 25, 2024
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [<sup>18</sup>F]PSMA-1007 ImagingMoritz B Bastian, Caroline Burgard, Arne Blickle, et al.
Diagnostics (Basel, Switzerland)|April 12, 2025
[<sup>18</sup>F]FDG PET/CT of Langerhans Cell Histiocytosis with Vertebra PlanaTilman Speicher, Moritz B Bastian, Konstantinos Christofyllakis, et al.
Clinical Nuclear Medicine|April 29, 2025
Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-conceptTilman Speicher, Caroline Burgard, Florian Rosar, et al.
Clinical Nuclear Medicine|April 30, 2025
Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-conceptTilman Speicher, Caroline Burgard, Florian Rosar, et al.
Clinical Nuclear Medicine|December 3, 2024
First Successful In-Human Application of 225Ac-DOTA-LM3 Mono-PRRT for the Treatment of an Otherwise Therapy-Resistant Neuroendocrine Tumor (NET G3)Tilman Speicher, Caroline Burgard, Moritz Bastian, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 22, 2025
Advancing patient education in PRRT through large language models: challenges and potentialTilman Speicher, Moritz B Bastian, Arne Blickle, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 30, 2026
FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?Moritz B Bastian, Ionas Kyriakou, Florian Rosar, et al.
Frontiers in Medicine|March 31, 2025
Prediction of lesion-based response to PRRT using baseline somatostatin receptor PETAnas Aouf, Tilman Speicher, Arne Blickle, et al.
Nuclear Medicine and Molecular Imaging|February 10, 2026
Auger Emitting [<sup>161</sup>Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal CarcinomatosisFlorian Rosar, Arne Blickle, Moritz B Bastian, et al.
Theranostics|September 18, 2025
Pilot experience of [<sup>161</sup>Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registryFlorian Rosar, Caroline Burgard, Christine Petrescu, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Diagnostics (Basel, Switzerland)|October 25, 2024
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [<sup>18</sup>F]PSMA-1007 ImagingMoritz B Bastian, Caroline Burgard, Arne Blickle, et al.
Diagnostics (Basel, Switzerland)|April 12, 2025
[<sup>18</sup>F]FDG PET/CT of Langerhans Cell Histiocytosis with Vertebra PlanaTilman Speicher, Moritz B Bastian, Konstantinos Christofyllakis, et al.
Clinical Nuclear Medicine|April 29, 2025
Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-conceptTilman Speicher, Caroline Burgard, Florian Rosar, et al.
Clinical Nuclear Medicine|April 30, 2025
Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-conceptTilman Speicher, Caroline Burgard, Florian Rosar, et al.
Clinical Nuclear Medicine|December 3, 2024
First Successful In-Human Application of 225Ac-DOTA-LM3 Mono-PRRT for the Treatment of an Otherwise Therapy-Resistant Neuroendocrine Tumor (NET G3)Tilman Speicher, Caroline Burgard, Moritz Bastian, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 22, 2025
Advancing patient education in PRRT through large language models: challenges and potentialTilman Speicher, Moritz B Bastian, Arne Blickle, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 30, 2026
FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?Moritz B Bastian, Ionas Kyriakou, Florian Rosar, et al.
Frontiers in Medicine|March 31, 2025
Prediction of lesion-based response to PRRT using baseline somatostatin receptor PETAnas Aouf, Tilman Speicher, Arne Blickle, et al.
Nuclear Medicine and Molecular Imaging|February 10, 2026
Auger Emitting [<sup>161</sup>Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal CarcinomatosisFlorian Rosar, Arne Blickle, Moritz B Bastian, et al.
Theranostics|September 18, 2025
Pilot experience of [<sup>161</sup>Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registryFlorian Rosar, Caroline Burgard, Christine Petrescu, et al.
Pageof 3